Immix Biopharma, Inc. – NASDAQ:IMMX
Immix Biopharma stock price today
$2.3
+0.05
+2.68%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 34 minutes
Immix Biopharma stock price monthly change
+6.16%
month
Immix Biopharma stock price quarterly change
+6.16%
quarter
Immix Biopharma stock price yearly change
-67.72%
year
Immix Biopharma key metrics
Market Cap | 56.94M |
Enterprise value | N/A |
P/E | -3.07 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.95 |
Revenue | N/A |
EBITDA | -18.89M |
Income | -18.20M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeImmix Biopharma stock price history
Immix Biopharma stock forecast
Immix Biopharma financial statements
| Jun 2023 | 0 | -3.57M | |
|---|---|---|---|
| Sep 2023 | 0 | -4.28M | |
| Dec 2023 | 4.78K | -5.08M | -106385.95% |
| Mar 2024 | 0 | -5.25M |
| 2025 | 0 | -26.59M | |
|---|---|---|---|
| 2026 | 12.14M | -10.10M | -83.2% |
| 2027 | 48.15M | 14.39M | 29.89% |
| 2028 | 109.87M | 47.34M | 43.09% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-09 | -0.23 | -0.23 |
|---|---|---|
| 2024-03-29 | -0.23 | -0.24 |
| 2024-05-09 | -0.23 | -0.22 |
| Jun 2023 | 15566487 | 2.39M | 15.39% |
|---|---|---|---|
| Sep 2023 | 22474778 | 2.82M | 12.57% |
| Dec 2023 | 19925160 | 3.72M | 18.68% |
| Mar 2024 | 34347592 | 6.71M | 19.55% |
| Jun 2023 | -3.51M | 0 | 4.69M |
|---|---|---|---|
| Sep 2023 | -3.08M | -38.91K | 10.06M |
| Dec 2023 | -2.67M | -13.17K | 586.69K |
| Mar 2024 | -3.82M | -301.91K | 15.94M |
Immix Biopharma alternative data
| Aug 2023 | 9 |
|---|---|
| Sep 2023 | 9 |
| Oct 2023 | 9 |
| Nov 2023 | 9 |
| Dec 2023 | 9 |
| Jan 2024 | 9 |
| Feb 2024 | 9 |
| Mar 2024 | 9 |
| Apr 2024 | 9 |
| May 2024 | 14 |
| Jun 2024 | 14 |
| Jul 2024 | 14 |
Immix Biopharma other data
3.67%
-7.78%
of IMMX is owned by hedge funds
134.95K
-285.79K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 8800 | 0 |
| Jun 2024 | 11700 | 0 |
| Jul 2024 | 9200 | 0 |
| Aug 2024 | 33100 | 0 |
| Dec 2024 | 47700 | 0 |
-
What's the price of Immix Biopharma stock today?
One share of Immix Biopharma stock can currently be purchased for approximately $2.3.
-
When is Immix Biopharma's next earnings date?
Unfortunately, Immix Biopharma's (IMMX) next earnings date is currently unknown.
-
Does Immix Biopharma pay dividends?
No, Immix Biopharma does not pay dividends.
-
How much money does Immix Biopharma make?
Immix Biopharma has a market capitalization of 56.94M. Immix Biopharma made a loss 15.43M US dollars in net income (profit) last year or -$0.22 on an earnings per share basis.
-
What is Immix Biopharma's stock symbol?
Immix Biopharma, Inc. is traded on the NASDAQ under the ticker symbol "IMMX".
-
What is Immix Biopharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Immix Biopharma?
Shares of Immix Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Immix Biopharma have?
As Jul 2024, Immix Biopharma employs 14 workers, which is 56% more then previous quarter.
-
When Immix Biopharma went public?
Immix Biopharma, Inc. is publicly traded company for more then 3 years since IPO on 16 Dec 2021.
-
What is Immix Biopharma's official website?
The official website for Immix Biopharma is immixbio.com.
-
Where are Immix Biopharma's headquarters?
Immix Biopharma is headquartered at 11400 West Olympic Boulevard, Los Angeles, CA.
-
How can i contact Immix Biopharma?
Immix Biopharma's mailing address is 11400 West Olympic Boulevard, Los Angeles, CA and company can be reached via phone at +31 6518041.
Immix Biopharma company profile:
Immix Biopharma, Inc.
immixbio.comExchange:
NASDAQ
Full time employees:
14
Industry:
Biotechnology
Sector:
Healthcare
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
11400 West Olympic Boulevard
Los Angeles, CA 90064
Los Angeles, CA 90064
CIK: 0001873835
ISIN: US45258H1068
CUSIP: 45258H106
